Pinar Demir1, Fusun Erdenen2, Hale Aral3, Turker Emre4, Sennur Kose4, Esma Altunoglu4, Anil Dolgun5, Berrin Bercik Inal3, Aydin Turkmen6. 1. Department of Internal Medicine, Ministry of Health Okmeydani Research and Training Hospital, Istanbul, Turkey. 2. Department of Internal Medicine, Ministry of Health Istanbul Research and Training Hospital, Istanbul, Turkey. fusunozerdenen@hotmail.com. 3. Department of Medical Biochemistry, Ministry of Health Istanbul Research and Training Hospital, Istanbul, Turkey. 4. Department of Internal Medicine, Ministry of Health Istanbul Research and Training Hospital, Istanbul, Turkey. 5. Department of Biostatistics, Medical Faculty, Hacettepe University, Ankara, Turkey. 6. Department of Nephrology, Istanbul Medical Faculty, Istanbul University, Istanbul, Turkey.
Abstract
BACKGROUND: To evaluate osteoprotegerin (OPG) levels in relation to cardiovascular (CV) risk factors in patients with chronic kidney disease (CKD) on different regimens of renal replacement therapy. METHODS: A total of 143 patients with CKD and 30 healthy controls were included in this study and divided into five categories, including predialysis patients with chronic renal failure (preD; n = 36), chronic peritoneal dialysis patients (PD; n = 36), hemodialysis patients (HD; n = 35), renal transplant patients (RT; n = 36), and controls (n = 30). Data on demographics, concomitant diseases and CV risk factors, serum OPG levels, and correlates of serum OPG levels were determined. RESULTS: Serum OPG (pmol/l) levels were significantly higher in HD (P <0.001 for each), PD (P <0.001 for each), and preD (P <0.01 vs. control, P <0.05 vs. RT) groups than RT and control groups. Diabetics than nondiabetics in HD (P = 0.008), PD (P = 0.024), and RT (P = 0.004) groups and males than females in PD group (P = 0.021) had higher OPG levels. Serum OPG levels were associated positively with age in HD (P <0.001), PD (P = 0.001), and in overall population (P <0.001). CONCLUSION: Our findings revealed increased serum levels of OPG in dialysis and preD patients compared to RT and controls. In the patient groups receiving two dialysis treatment, the levels were worse, indicating a more pronounced vascular injury. Age, C-reactive protein (CRP), high-density lipoprotein cholesterol (HDL-C), and cystatin C (CysC) in CKD patients, CRP and PTH in the control subjects, and age and BMI in the overall population were the significant correlates of serum OPG levels.
BACKGROUND: To evaluate osteoprotegerin (OPG) levels in relation to cardiovascular (CV) risk factors in patients with chronic kidney disease (CKD) on different regimens of renal replacement therapy. METHODS: A total of 143 patients with CKD and 30 healthy controls were included in this study and divided into five categories, including predialysis patients with chronic renal failure (preD; n = 36), chronic peritoneal dialysis patients (PD; n = 36), hemodialysis patients (HD; n = 35), renal transplant patients (RT; n = 36), and controls (n = 30). Data on demographics, concomitant diseases and CV risk factors, serum OPG levels, and correlates of serum OPG levels were determined. RESULTS: Serum OPG (pmol/l) levels were significantly higher in HD (P <0.001 for each), PD (P <0.001 for each), and preD (P <0.01 vs. control, P <0.05 vs. RT) groups than RT and control groups. Diabetics than nondiabetics in HD (P = 0.008), PD (P = 0.024), and RT (P = 0.004) groups and males than females in PD group (P = 0.021) had higher OPG levels. Serum OPG levels were associated positively with age in HD (P <0.001), PD (P = 0.001), and in overall population (P <0.001). CONCLUSION: Our findings revealed increased serum levels of OPG in dialysis and preD patients compared to RT and controls. In the patient groups receiving two dialysis treatment, the levels were worse, indicating a more pronounced vascular injury. Age, C-reactive protein (CRP), high-density lipoprotein cholesterol (HDL-C), and cystatin C (CysC) in CKDpatients, CRP and PTH in the control subjects, and age and BMI in the overall population were the significant correlates of serum OPG levels.
Authors: Joshua R Lewis; Wai H Lim; Kun Zhu; Germaine Wong; Satvinder S Dhaliwal; Ee M Lim; Thor Ueland; Jens Bollerslev; Richard L Prince Journal: Am J Nephrol Date: 2014-01-21 Impact factor: 3.754
Authors: T Sato; Y Tominaga; Y Iwasaki; J J Kazama; T Shigematsu; H Inagaki; I Watanabe; A Katayama; T Haba; K Uchida; M Fukagawa Journal: Am J Kidney Dis Date: 2001-10 Impact factor: 8.860
Authors: Stefan Kiechl; Georg Schett; Gregor Wenning; Kurt Redlich; Martin Oberhollenzer; Agnes Mayr; Peter Santer; Josef Smolen; Werner Poewe; Johann Willeit Journal: Circulation Date: 2004-04-26 Impact factor: 29.690
Authors: Diana Moldovan; Crina Rusu; Alina Potra; Ioan Moldovan; Ioan Mihai Patiu; Mirela Gherman-Caprioara; Ina Maria Kacso Journal: Int Urol Nephrol Date: 2017-02-04 Impact factor: 2.370